Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma

NCT04853329 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

7

Enrollment

INDUSTRY

Sponsor class

Stopped Business reasons

Conditions

CD20 Positive Non Hodgkin Lymphoma

Interventions

DRUG: CPO107

Sponsor

Conjupro Biotherapeutics, Inc.